Aug 30, 2024

Featuring an interview with Dr Michiel van der Heijden, including the following topics:

• Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00)
• Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adverse events (3:15)
• Activity of anti-PD1/PD-L1 and anti-CTLA4 combinations for patients with bladder cancer; role of circulating and urinary tumor DNA in urothelial carcinoma (6:40)
• Case: A 61-year-old woman with metastatic urothelial bladder cancer (mUBC) treated with first-line enfortumab vedotin and pembrolizumab (19:34)
• Case: A 63-year-old man with extensive mUBC whose disease progresses on avelumab maintenance receives enfortumab vedotin (25:54)

CME information and select publications